Fundamentals Are Strong, page-39

Pharma is an M&A-driven business. At the moment, the larger players (like Teva and Mylan) are under a bit of pressure, so activity might be constrained.

MYX might come across opportunities to buy product portfolios from debt-stricken competitors (neglected, non-core assets that they can add value to). If there's the possibility to finance acquisitions using existing earnings, as well as a small amount of debt (keeping gearing to sensible levels), then these could be attractive.

Danginvestor made a good point that MYX has raised a lot of capital from its shareholders in recent years. The most recent raising was an institutional placement at $1.50. Until the price is around the $2 mark, I think that any further capital raising should only be done in exceptional circumstances.

On the other side of the coin, there's always the possibility that MYX could divest part of its portfolio (there hasn't been any talk about this in the investor communications), or that they could be a takeover target (the share price is low, but larger players are probably not focused on such a move right now).

Most likely the company will keep trading, business as usual, and hopefully the cash inflow will be enough to stabilise and grow the share price. Their target to triple revenue to $1.5bn by 2021 seems ambitions - not sure if they will achieve that, but I suppose it is good to aim high.